Vaccine candidate has the potential to be the first available to help protect adults aged 60 years and older from lower respiratory tract disease caused by respiratory syncytial virus Application… Read More
Third approved indication for SKYRIZI® (risankizumab) and the first specific IL-23 inhibitor for the treatment of Crohn’s disease in the European Union (EU) A significantly higher proportion of patients on SKYRIZI achieved clinical… Read More
VANCOUVER, BC — Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the publication of an abstract highlighting new clinical data for zanidatamab, a HER2-targeted bispecific… Read More
TORONTO, ON — Takeda Canada Inc. (“Takeda”) is pleased to announce that TAKHZYRO® (lanadelumab), the first approved monoclonal antibody for the treatment of Hereditary Angioedema (HAE) has been named the 2022… Read More
VANCOUVER, BC — InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announced the… Read More
